Citations 2
VP-16, Cyclophosphamide, Adriamycin and Cis-platinum (V:CAP-I) in Patients with Metastatic Adenocarcinoma of the Lung
Eagan, Robert T., Creagan, Edward T. , Rubin, Joseph, Frytak, Stephen, Kvols, Larry K., Fleming, Thomas R. , Ingle, James N.
Tumori Journal | April 23, 2018 | Volume: 65 | Issue: 1 | Pages: 105-109
In an attempt to improve upon the 42% regression rate of the CAP-I regimen in patients with advanced adenocarcinoma of the lung, VP-16 was added to that regimen. VP-16, as a single agent, had a response rate of 12.5% (3/24) in a similar group of patients. The new regimen, V:CAP-I, had a tumor regression rate of 35% (7/20) and an estimated median survival of 171 days. Hence, we were unable to conclude that the addition of VP-16 to the CAP-I regimen statistically improved the regression rate of the CAP-I regimen.
Adriamycin and Radiation Reaction
Eagan, Robert T., LEE, ROBERT E., CARR, DAVID T., LEE, ROBERT E., CARR, DAVID T.
Annals of Internal Medicine | April 12, 2013 | Volume: 86 | Issue: 2 | Pages: 243-244